Pharmaceutical - Asia-Pacific, Pfizer


Current filters:


Popular Filters

India’s IPAB upholds Pfizer’s Detrol patent

India’s IPAB upholds Pfizer’s Detrol patent


In a positive development for US drug giant Pfizer, India's Intellectual Property Appellate Board (IPAB)…

Asia-PacificDetrolGenito-urinaryIndiaPatentsPfizerPharmaceuticalRanbaxy Laboratories

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia

ACCC acts on Pfizer’s alleged anti-competitive conduct in Australia


The Australian Competition and Consumer Commission revealed today that is has instituted proceedings…

Asia-PacificAustraliaCardio-vascularLegalLipitorMarkets & MarketingPfizerPharmaceutical

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India


Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…


Leading Chinese hepatitis B vaccine makers stop production; Pfizer drug import halted


China’s Food and Drug Administration announced on January 2 that the country’s three leading manufacturers…

Anti-viralsAntibiotics and Infectious diseasesAsia-PacificBioKangtaiChinaFluconazolePfizerPharmaceuticalRegulationVaccines

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report


Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Nippon Shinyaku and Pfizer conclude exclusive sales promotion on Tramal


Nippon Shinyaku and Pfizer have concluded an exclusive sales promotion consignment contract in Japan…

Asia-PacificLicensingMarkets & MarketingNeurologicalNippon ShinyakuPfizerPharmaceuticalTramadol Hydrochloride

Pfizer, GSK and Siemens join R&D consortium with A*STAR' on pharma production


US and UK pharma giants Pfizer (NYSE: PFE) and GlaxoSmithKline's (LSE: GSK) units Pfizer Asia Pacific…


Indian IPAB provides relief for Pfizer in Sutent patent revocation case


India's Intellectual Property Appellate Board (IPAB) has provided global pharma behemoth Pfizer (NYSE:…


Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives


Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…


India's Cipla cuts prices of three cancer drugs


Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Another negative Indian patent ruling, this time for Pfizer's Sutent


In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

Pfizer launches generics JV in China with Hisun


Global drugs behemoth Pfizer (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE Code: 600267), a leading…

Asia-PacificGenericsHisun-PfizerMergers & AcquisitionsPfizerPharmaceuticalZhejiang Hisun Pharma

Pfizer in $60 million settlement over bribery charges


US drugs behemoth Pfizer (NYSE: PFE) said yesterday that it has agreed to pay a total of $60 million…

Asia-PacificEuropeFinancialLegalMarkets & MarketingPfizerPharmaceuticalWyeth

Takeda loses distribution of 13 Pfizer products in Japan


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) has concluded an agreement that, as of December…

Asia-PacificBenefixEnbrelLicensingMarkets & MarketingPfizerPharmaceuticalPrevenarTakeda Pharmaceuticals

Pfizer and Biocon cancel biosimilars deal


Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

India’s new drug price control will damage pharma sector, says local Pfizer chief


The recent moves by India’s government to control the prices of all 348 essential drugs – accounting…

Asia-PacificMergers & AcquisitionsPfizerPharmaceuticalPricing

Back to top